AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03643341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Healthy Living
Description: Children aged 8-12 and at least one caregiver will meet for 10 weekly intervention sessions (1.5 hours per session), and 4 extra sessions to be chosen by families and intervention Leaders. During the intervention, participants will also have access to digital educational content that is supplementary to what is provided during the individual sessions. Four biweekly maintenance sessions will follow the main program.
Study NCT04033315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: L-PLUS meter
Description: Blood Glucose Monitoring System
Study NCT00909324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-LASIK 0.3% hypromellose
Description: Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting 5 days prior to LASIK surgery and continuing through 1 month after LASIK surgery.
Study NCT01036581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagPro X100 Magnetic Stimulator
Description: Concurrent TMS-MRI acquisition allows us to investigate the acute effects of induced brain activity on BOLD signal and evaluate interference of the TMS pulse with the BOLD signal measurement.
Study NCT01036581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Rotating Magnetic Stimulator
Description: Participants will undergo transcranial rapid rotating permanent magnetic stimulation (TRPMS), with the aim of evaluating the prolonged effect of TRPMS on motor cortex excitability. In another experiment, participants will undergo TRPMS with the aim of evaluating cortical excitability changes with TRPMS. These experiments will help interpret subsequent experiments investigating the effect of TRPMS on BOLD signal.
Study NCT01036581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetom Prisma Fit 3T Scanner
Description: Type: MRI Name: Magnetom Prisma Fit 3T Scanner (Siemens) Description: Functional and structural magnetic resonance imaging techniques are used for noninvasive mapping of brain physiology and pathology and to develop advanced magnetic resonance imaging and spectroscopy (MRI and MRS) techniques for neuroimaging studies related to addiction.
Study NCT01362803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: AZD6244 orally (at recommended Ph2 dose) every 12 hours on continuous daily schedule for cycles of 28 days until unacceptable toxicity, patient withdrawal or PD
Study NCT02858336 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NEA
Description: Neutral Energy Availability: 5-day outpatient intervention of prescribed diet and exercise to elicit an energy availability of 45 kcal/kg LBM day.
Study NCT02858336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DEA
Description: Deficient Energy Availability: 5-day outpatient intervention of prescribed diet and exercise to elicit an energy availability of 20 kcal/kg LBM day.
Study NCT03907826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 blocking antibody
Description: Toripalimab 240mg, D1, every 3 weeks per cycle
Study NCT03907826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GP
Description: Gemcitabine 1.0g/m2, D1 and D8; Cisplatin 80mg/m2, D1, every 3 weeks per cycle, total three cycles
Study NCT03907826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP
Description: Gemcitabine 1.0g/m2, D1 and D8; Cisplatin 80mg/m2, D1, every 3 weeks per cycle, total three cycles
Study NCT03907826 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: IMRT 60-66Gy, 1.8-2.0Gy/f/day
Study NCT03907826 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: IMRT 60-66Gy, 1.8-2.0Gy/f/day
Study NCT04317677 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Study of the effect of bladder voiding on sleep fragmentation during day and night sleep
Description: Vigilance state of babies will be continuously recorded during the first 24 hours of hospitalization by polysomnography and actigraphy. In parallel, bladder voiding episodes will be detected with an innovative device placed on babies diapers.
Study NCT00909324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post-LASIK 0.3% hypromellose
Description: Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting on the day of LASIK surgery and continuing through 1 month after surgery.
Study NCT03666468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PlayMed
Description: A highly immersive role-playing computer game focused on Paediatric Asthma and Seizure management
Study NCT01887561 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: dasatinib
Study NCT02305472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeoVas BCS
Description: Subjects receiving NeoVas BCS
Study NCT05073796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlea Implant
Description: * examination and documentation of vital signs and concomitant medication~* application of an cochlea implant loan processor (external body surface) with varying stimulus pattern for vestibular stimulation by means of basal, medial and apical electrodes~* attraction of an special mask to determine the subjective visual vertical (SVV)~* assessment of the vertical spatial axis with all electrodes turned off~* assessment of the vertical spatial axis with all electrodes turned on~* assessment of the vertical spatial axis while using basal (12-16) and medial (6-11) electrodes~* assessment of the vertical spatial axis while using basal (12-16) and apical (1-5) electrodes~* assessment of the vertical spatial axis while using medial (6-11) and apical (1-5) electrodes
Study NCT02450461 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT03895580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-store POP education
Description: Six in-store nutrition counseling sessions with a registered dietitian nutritionist.
Study NCT03895580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online POP education
Description: Education on the use of an online grocery shopping, an online recipe tool, a grocery pickup service, a home grocery delivery service, and a phone application that promotes healthy food selection.
Study NCT00778375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: 20 mg/m\^2 by vein as a 1- to 2-hour intravenous infusion daily for 5 days.
Study NCT00778375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 20 mg subcutaneously twice daily for 10 days, administered 3 to 6 hours following the start of the clofarabine infusions.
Study NCT00778375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20 mg/m\^2 as a 1- to 2-hour infusion daily for 5 days.
Study NCT03220464 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultra low dose chest computed tomography (ULDCT)
Description: Participants in the study will receive ULDCT at enrollment, after 3-month visit, and after 12-month visit.
Study NCT01876160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Study NCT01648946 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell transfusion
Description: Red blood cell (RBC) transfusion will be given when hemoglobin falls below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of hemoglobin levels is performed; if a patient's hemoglobin level is 9 g/dL or higher, no additional transfusion is necessary.
Study NCT01648946 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell transfusion
Description: Red blood cell (RBC) transfusion will be only given when hemoglobin falls below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of the hematocrit is performed; if a patient's hemoglobin is 7 g/dL or higher, no additional transfusion is necessary.
Study NCT01035515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose oral capsule placebo comparator
Study NCT01035515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB014 50mg
Description: Single dose oral capsule 50mg BIIB014
Study NCT01512589 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Therapy (PBT)
Description: 1.8 Gy (Relative Biologic Equivalence ((RBE)) to be delivered to the periphery of the planning target volume (PTV) 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments.
Study NCT01512589 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: 1.8 Gy to be delivered to the periphery of the planning target volume (PTV) 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments.
Study NCT01512589 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Symptom and Quality of Life questionnaires completed at baseline, every week during radiation therapy, during break after radiation therapy, and during follow up phase.
Study NCT01512589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Symptom and Quality of Life questionnaires completed at baseline, every week during radiation therapy, during break after radiation therapy, and during follow up phase.
Study NCT04214262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT04214262 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04214262 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04214262 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study NCT04214262 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study NCT04214262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG PET/CT
Study NCT04214262 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG PET/CT
Study NCT04214262 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT03220464 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chest X-ray
Description: Participants in the study will receive chest x-ray at enrollment, after 3-month visit, and after 12-month visit.
Study NCT03220464 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Interferon-gamma Release Assay (IGRA)
Description: Participants in the study will receive IGRA test at enrollment, after 3-month visit, and after 12-month visit. About 11mL of blood will be drawn from the participants for test of T-SPOT®.TB test and QuantiFERON test.
Study NCT03287934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: selective laser sintered stent
Description: after planning and virtual implant placement, a guide will be designed and the STL file will be send to prototyping center for printing the guide with selective laser sintering technique. during the surgical procedure , the target tooth will be atraumatic extracted, the stent is adapted in its place then implant drilling and placement will be done.
Study NCT03287934 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: selective laser sintered stent
Description: after planning and virtual implant placement, a guide will be designed and the STL file will be send to prototyping center for printing the guide with selective laser sintering technique. during the surgical procedure , the target tooth will be atraumatic extracted, the stent is adapted in its place then implant drilling and placement will be done.
Study NCT04214262 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT04214262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04214262 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03287934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: digital light processing(dlp)
Description: after planning and virtual implant placement, a guide will be designed and the STL file will be send to prototyping center for printing the guide with digital light processing technique. during the surgical procedure , the target tooth will be atraumatic extracted, the stent is adapted in its place then implant drilling and placement will be done.
Study NCT03287934 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: digital light processing(dlp)
Description: after planning and virtual implant placement, a guide will be designed and the STL file will be send to prototyping center for printing the guide with digital light processing technique. during the surgical procedure , the target tooth will be atraumatic extracted, the stent is adapted in its place then implant drilling and placement will be done.
Study NCT04103944 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Core Decompression
Description: 10 patients will be randomized chosen in this group
Study NCT04103944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteonecrotic Repair Device
Description: 10 patients will be randomized chosen in this group
Study NCT04214262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04214262 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02753907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low LA
Description: Individuals who replaced 10 mL soy oil with one apple
Study NCT02753907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High LA
Description: Individuals who reduced 1/3 cup of cooked refined rice and consumed 9.9g (9 of 1.1g capsules, 3 capsules at every 3 meals a day) of soy oil as a supplement
Study NCT04192136 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside
Description: Investigators will use (Good Manufacturing Process) GMP-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA).~NR is distributed by ChromaDex, Inc., Irvine, CA. NR is available as 300 mg capsules.~The dietary supplement will be re-labeled by the Hospital of the University of Pennsylvania (HUP) Investigational Drug Service according to FDA regulations, including subject and physician name and NR or Placebo 300 mg capsules.
Study NCT04192136 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule).
Study NCT04192136 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule).
Study NCT04192136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: The exercise program consists of at-home training sessions: 3 aerobic sessions per week on the in-home bike trainer, and 2 resistance exercise sessions per week using resistance bands.~On aerobic training days, subjects will be given instruction on a recumbent Catrike trainer, titrated such that they spend 20 minutes at their target heart rate as determined by baseline Exercise Stress Test (EST) (60-80% of their heart rate at peak VO2) and as measured by their wearable device.~On resistance training days, subjects will be given instructions to complete circuits of resistance exercises. Resistance training intensity (as determined by graded resistance bands) will be maintained at 60% of pre-training maximal voluntary contraction for each muscle group.
Study NCT04009694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle training
Description: Sixteen weeks of supervised pelvic floor muscle training with a specialist physiotherapist
Study NCT03231917 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Water Infusion first
Description: In this group patients will receive a colonoscopy with water infusion for mucosal inspection and then receive a colonoscopy with CO2 insufflation.
Study NCT03231917 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CO2 Insufflation First
Description: In this group patients will receive a colonoscopy with CO2 insufflation for mucosal inspection and then receive a colonoscopy with water infusion .
Study NCT00442533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indium-111 pentetreotide
Description: 4 cycles of 500 mCi treatments every 10-12 weeks
Study NCT04214262 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT04214262 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT01764477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRI-724
Description: Gemcitabine: 1000 mg/m2 IV over 30 minutes; once weekly dosing; 3 weeks on with 1 week recovery (4 weeks per cycle)~PRI-724:~Cohort 1: 320 mg/m2/day; Cohort 2: 640 mg/m2/day; Cohort 3: 905 mg/m2/day; Continuous IV over 24 hours; daily x 7 days; 1 week on with 1 week recovery × 2 (4 weeks per cycle)
Study NCT03935672 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: PET-CT scans
Description: Patients will have three scans during the trial.~* The 1st scan (prePET) is a baseline diagnostic scan. The patient is in a thermoplastic shell and PET CT will be used by to define a bGTV_P. bGTV_P will then be used as an adjunct to help us delineate the GTV_P.~* The 2nd scan (iPET) takes place following 2 weeks (10 fractions) of chemo-radiotherapy. The patient is in a thermoplastic shell and the PET CT will be used to delineate the remaining avid disease (bGTV_iP).~* The 3rd scan takes place 3 months following the last dose of radiotherapy. It will be used to ascertain whether any avid disease remains and may inform the need for further treatment.
Study NCT03935672 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Outlining the biological GTVs (bGTV_P and bGTV_iP)
Description: The biological GTVs (bGTV_P and bGTV_iP) will be automatically delineated by ATLAAS and verified manually by a nuclear medicine physician and a clinical oncologist. It will consist of the high FDG uptake volume based on visual assessment whilst using suitable windowing levels. Any differences in contouring will be settled either by the two doctors reaching a consensus or by a third doctor if differences between the first two cannot be resolved.
Study NCT03935672 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood samples for cell-free DNA analysis
Description: In order to contribute to our understanding of how disease processes may be monitored in a less invasive and less morbid manner, we will be collecting blood and saliva samples prior to, during, and after the radical treatment of OPSCC in PEARL, to see if there is correlation with disease status and FDG-PET-CT response.
Study NCT03935672 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Salivary samples for cell-free DNA analysis
Description: In order to contribute to our understanding of how disease processes may be monitored in a less invasive and less morbid manner, we will be collecting blood and saliva samples prior to, during, and after the radical treatment of OPSCC in PEARL, to see if there is correlation with disease status and FDG-PET-CT response.
Study NCT04145544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of the ArtiFascia®
Description: Following are the general instructions for use for the ArtiFascia®:~* Cut the ArtiFascia® to the required shape under aseptic conditions~* Apply ArtiFascia® to the damaged area~* Suture the ArtiFascia® in place~* Suture bites should be taken 2-3 millimeters from the edges of the implant. Either a running suture or interrupted stitches' technique may be used, depending on clinical conditions or surgeon's decision.~Important Note: If clinically possible, do not use dural adhesive or sealants as it is an uncontrolled variable, that can influence the results.
Study NCT04145544 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of other commercial suturable dural substitute
Description: Implantation of the commercial suturable dural substitute will be according to clinical discretion of the physician, and in compliance with each specific device instructions for use. Detailed instructions are in the instructions for use
Study NCT00599534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: 4 mg oral tablets
Study NCT00599534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5mg tablets
Study NCT04044053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571 400 mg Immediate Release (IR) in Fed State
Description: 400 mg IR dose in fed state
Study NCT04044053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571 50 mg Modified Release (MR) in Fed State
Description: 50 mg MR in fed state